Biocept, Inc. (B00.F)

6.80 0.00 (0.00%) 收市：08:04AM CEST

Biocept, Inc.

9955 Mesa Rim Road
San Diego, CA 92121
United States
858 320 8200
https://biocept.com

版塊: 
行業: 
全職員工: 50

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Darrell Taylor Esq.	Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Registered In-House Counsel	402.25k	無	1965
Dr. Soon Kap Hahn Ph.D.	Founder	無	無	無
Mr. Rob Walsh	VP & Controller	無	無	無
Dr. Philippe J. Marchand Ph.D.	Chief Operating Officer	無	無	1963
Mr. Pavel Tsinberg	Director of Technology Development	無	無	無
Mr. David S. Moskowitz R.Ph., MBA	Vice President of Strategy & Corporate Communications	無	無	無
Dr. Veena M. Singh	Senior Medical Director	335.96k	無	1975

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

公司管治

截至 無 止，Biocept, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。